FTH
Faeth Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Faeth Therapeutics, Inc.
18.32
No N-PORT holders.
—
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Suvretta Capital ManagementSuvretta | $50.5M | 14.35% | +5747.07% | |
| 2 | venBio Select AdvisorvenBio Select Advisor | $36.1M | 10.26% | new | |
| 3 | Baker Bros. AdvisorsBaker Bros. | $32.2M | 9.14% | new | |
| 4 | Balyasny Asset ManagementBalyasny | $26.1M | 7.41% | +6331.34% | |
| 5 | Cormorant Asset ManagementCormorant | $25.7M | 7.31% | +235.78% | |
| 6 | RA Capital ManagementRA Capital Management | $18.1M | 5.13% | new | |
| 7 | Vivo CapitalVivo Capital | $18.1M | 5.13% | 0.00% | |
| 8 | Logos Global ManagementLogos Global | $18.1M | 5.13% | +2306.73% | |
| 9 | Fairmount Funds ManagementFairmount Funds | $18.1M | 5.13% | new | |
| 10 | Caligan PartnersCaligan Partners | $15.7M | 4.47% | +399.57% | |
| 11 | B GroupB Group | $15.3M | 4.34% | new | |
| 12 | Trails Edge Capital PartnersTrails Edge Capital Partners | $12.9M | 3.66% | +312.27% | |
| 13 | Franklin ResourcesFranklin Resources | $12.4M | 3.51% | +270.41% | |
| 14 | Octagon Capital AdvisorsOctagon Capital | $9.0M | 2.57% | new | |
| 15 | ADAR1 Capital ManagementADAR1 | $9.0M | 2.57% | new | |
| 16 | Marshall WaceMarshall Wace | $5.2M | 1.47% | +214.18% | |
| 17 | Boxer Capital ManagementBoxer | $4.5M | 1.28% | new | |
| 18 | Patient Square CapitalPatient Square Capital | $4.4M | 1.24% | new | |
| 19 | Alyeska Investment GroupAlyeska Investment | $3.6M | 1.03% | new | |
| 20 | Affinity Asset AdvisorsAffinity Asset | $3.6M | 1.03% | new | |
| 21 | Boothbay Fund ManagementBoothbay Fund | $3.3M | 0.95% | +411.57% | |
| 22 | AWM InvestmentAWM Investment | $2.8M | 0.79% | new | |
| 23 | Richmond Investment ServicesRichmond Investment Services | $2.0M | 0.57% | new | |
| 24 | Ikarian CapitalIkarian Capital | $884,650 | 0.25% | +457.17% | |
| 25 | UBS GroupUBS | $538,525 | 0.15% | +375.62% |
45 managers report $351.8M of Faeth Therapeutics on form 13F for the quarter ended Jun 30 '26. 12 of them hold 80% of it; Suvretta is largest at 14.35%.
Linked news
NewsExpected move
No implied move.